课题基金 / 基金详情

Bacterial-type hexokinase (HK) in the opportunistic parasite Cryptosporidium parv

Bacterial-type hexokinase (HK) in the opportunistic parasite Cryptosporidium parv
机会性寄生虫隐孢子虫中的细菌型己糖激酶 (HK)
批准号:
8898712
负责人:
GUAN ZHU
金额:
$17.78万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2017-07-31

项目摘要

项目成果

GUAN ZHU的其他基金

相似基金

相关文献

中文摘要
翻译
描述:微小隐孢子虫是一种艾滋病OI病原体和B类病原体。它是一种重要的水和食物传播的原生动物寄生虫,可导致人和动物严重的水样腹泻。目前,在美国,只有一种药物(即硝唑尼特[NTZ])被批准用于治疗免疫功能正常(但不是免疫受损)患者的隐孢子虫病。然而,NTZ对隐孢子虫病并不是100%有效。隐孢子虫也可能产生潜在的耐药性,类似于疟疾寄生虫和球虫的耐药性问题。因此,迫切需要开发新的抗隐孢子虫药物。我们这项转译研究的长期目标是表征微小隐孢子虫糖酵解途径中关键酶的分子和生化特征,作为潜在的药物靶点。由于微小隐孢子虫的能量完全依赖于糖酵解,我们推测负责糖酵解反应进入步骤的细菌型CpHK可能是这种寄生虫的合理药物靶点。为了验证这一假设,我们将进行实验,以表征CpHK的生化特征,并通过化合物文库的HTS寻找CpHK抑制剂用于未来的药物开发,表征TOP HITS的抑制动力学,并在体外测试它们对微小弧菌生长的效果。这个探索性/发展性R21项目的主要目标是确定抑制CpHK 这将为进一步研究HITS的抑制机制、构效关系、合成新的HITS类似物以进行先导优化以及在动物模型中评估HITS和LEADS对隐孢子虫感染的疗效提供确凿的数据。
英文摘要
DESCRIPTION: Cryptosporidium parvum is an AIDS-OI pathogen and Category B agent. It is a significant water- and food-borne protozoan parasite that can cause severe watery diarrhea in humans and animals. Currently, only a single drug (i.e., nitazoxanide [NTZ]) is approved for treating cryptosporidiosis in immunocompetent (but not immunocompromized) patients in the United States. However, NTZ is not 100% effective against cryptosporidiosis. Potential drug resistance may also be developed in Cryptosporidium, similar to the drug resistance problem in malarial parasites and coccidia. Therefore, there is an urgent need to develop new anti-Cryptosporidium drugs. Our long-term goal of this translational research is to characterize the molecular and biochemical features of the essential enzymes in the C. parvum glycolytic pathway as potential drug targets. Because C. parvum relies solely on glycolysis for its energy, we hypothesize that the bacterial-type CpHK responsible for the entry step of reaction in the glycolytic pathways could serve as rational drug targets in this parasite. To test the hypothesis, we will perform experiments to characterize the biochemical features of CpHK and identify CpHK inhibitors for future drug development via HTS of compound libraries, characterize the inhibitory kinetics of top hits, and test their efficacies against C. parvum growth in vitro. The major goal of this exploratory/developmental R21 project is to identify hits that inhibit both CpHK enzyme activity and the parasite growth in vitro, which would produce conclusive data for further studying the mechanism of inhibition, structure-activity relationship, and to synthesize new analogs of hits for lead optimization, as well as to assess the efficacies of hits and leads agains cryptosporidial infection in animal models.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Developing Therapeutics against Giardia and Other Anaerobic Protozoa by Targeting Parasite Fatty Acyl-CoA Synthetase (ACS)
  • 批准号:
    9099754
  • 项目类别:
  • 资助金额:
    $19.9万
  • 财政年份:
    2015
  • 负责人:
    GUAN ZHU
  • 依托单位:
Bacterial-type hexokinase (HK) in the opportunistic parasite Cryptosporidium parv
  • 批准号:
    8730780
  • 项目类别:
  • 资助金额:
    $21.44万
  • 财政年份:
    2014
  • 负责人:
    GUAN ZHU
  • 依托单位:
Evaluation of marketed drugs for rapid development as anti-cryptosporidal agents
  • 批准号:
    8528014
  • 项目类别:
  • 资助金额:
    $18.61万
  • 财政年份:
    2012
  • 负责人:
    GUAN ZHU
  • 依托单位:
Evaluation of marketed drugs for rapid development as anti-cryptosporidal agents
  • 批准号:
    8285540
  • 项目类别:
  • 资助金额:
    $21.98万
  • 财政年份:
    2012
  • 负责人:
    GUAN ZHU
  • 依托单位:
海外基金